News Novartis eyes year-end filing in US for Fabhalta in C3G Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 gl
News Regeneron is off to CHAPLE as FDA starts pozelimab review The C5 inhibitor is vying to become the first approved drug for the ultra-rare immune disorder.
Events Partner Content Welcome to the 6th Complement-based Drug Development Summit ... Decipher Complement Pathway Intricacies, Validate Pathway Activation Assays & Discover Next-Generation Complement-Targeted Approaches that are
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends